« Back
Home /
AKT inhibitor VIII

AKT inhibitor VIII

Manufacturer	MedChem Express
Category	Oncology Neuroscience Metabolism Diabetes Molecular Targets for Neuroscience Targets for Rodent Neurosciences Aging & Neurological Disorders Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	100 mg
Item no.	HY-10355-100mg
Targets	Akt; Apoptosis
CASRN	612847-09-3
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity with IC50s of 58 nM, 210 nM, and 2119 nM, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	551.64
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer; Metabolic Disease
Solubility	DMSO : 20 mg/mL (ultrasonic)
Manufacturers Target	Akt; Apoptosis
Isoform	Akt1; Akt2; Akt3
Pathway	Apoptosis; PI3K/Akt/mTOR
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10355-100mg-safety-datasheet.pdf